DISCO Pharmaceuticals Announces Strategic Collaboration with AbbVie to Advance Next-Generation AND-Gated Bispecific Therapeutics for Solid Tumors

Cologne, Germany, November 19, 2026 – DISCO Pharmaceuticals (“DISCO”) today announced a strategic collaboration and option- to-license agreement with AbbVie to discover and develop novel AND-gated bispecific therapeutics for solid tumors with high unmet medical need.

Under the terms of the agreement, DISCO will receive $40 million in upfront payments and is eligible for up to $2.5 billion in option, development, and other milestone payments, plus tiered royalties on worldwide net sales

“The collaboration with AbbVie represents an important opportunity to deliver the next generation of precision medicines to patients with difficult-to-treat solid tumors,” said Mark Manfredi, Ph.D., CEO of DISCO Pharmaceuticals. “Our AND-gated approach is designed to selectively target tumor cells while sparing healthy tissue, thus offering a potentially differentiated path in precision oncology. Our DISCOtech® platform’s unique ability to identify tumor-selective target pairs provides the foundation for therapies with the potential for a wider therapeutic window.”

“We look forward to working together with AbbVie towards the shared goal of creating transformative therapeutics for patients. This collaboration further underscores the potential of our differentiated platform and complements our portfolio of internal and partnered pipeline programs,” added Ajla Hrle, Ph.D., CBO of DISCO Pharmaceuticals.

DISCO Pharmaceuticals is headquartered in Cologne, Germany, and has a subsidiary in the Bio-Technopark Schlieren-Zurich.

back